Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 2—February 2015
Dispatch

Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses

Andrea Marzi, Friederike Feldmann, Thomas W. Geisbert, Heinz Feldmann, and David SafronetzComments to Author 
Author affiliations: National Institutes of Health, Hamilton, Montana, USA (A. Marzi, F. Feldmann, H. Feldmann, D. Safronetz); University of Texas Medical Branch, Galveston Texas, USA (T.W. Geisbert)

Main Article

Table

Serologic responses in 3 nonhuman primates sequentially vaccinated with 2 VSV-based VHF vaccines*

Prechallenge Postchallenge Prechallenge Postchallenge
LASV GPC
 LASV GPC
 LASV NP
 VSV
 EBOV GP
 EBOV GP
 EBOV VP40
 VSV
1 ND ND 100 25,600 6,400 25,600 1,600 102,400
2 ND ND <100 25,600 6,400 25,600 6,400 102,400
3 ND ND <100 25,600 6,400 25,600 6,400 102,400

*VSV, vesicular stomatitis virus; VHF, viral hemorrhagic fever; LASV, Lassa virus; GPC, glycoprotein precursor; NP, nucleocapsid protein; EBOV, Ebola virus; GP, glycoprotein; VP40 viral protein 40; ND, not determined. Titers are indicated as reciprocal endpoint dilutions from ELISAs for recombinant antigens (LASV NP, EBOV GP, and VP40), or whole virus preparations (VSV).

Main Article

Page created: January 21, 2015
Page updated: January 21, 2015
Page reviewed: January 21, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external